Mental Retardation
Welcome,         Profile    Billing    Logout  
 108 Companies   17 Products   17 Products   10 Mechanisms of Action   903 Trials   97461 News 


«12345678910111213...17211722»
  • ||||||||||  Journal:  Structure-Based Modeling of the Gut Bacteria-Host Interactome Through Statistical Analysis of Domain-Domain Associations Using Machine Learning. (Pubmed Central) -  Apr 14, 2025   
    Using statistical associations between Pfam domains, a comprehensive dataset of over one million experimentally validated pan-bacterial-human protein interactions, as well as inter- and intra-species protein interactions from various organisms, were used for the development of a machine learning-based prediction method to uncover key regulatory molecules in this dynamic system. This study's findings contribute to the understanding of the intricate gut microbiome-host relationship and pave the way for future experimental validation and therapeutic strategies targeting the gut microbiome interplay.
  • ||||||||||  Review, Journal:  Evolving role of the internet in China as a medium for promoting psychological well-being and mental health: a scoping review. (Pubmed Central) -  Apr 14, 2025   
    However, achieving this long-term goal will require establishing standardised methods of administering internet-based interventions, training mental health professionals to implement and monitor the interventions, identifying methods of maintaining the confidentiality of collected information, and rigorously assessing the effectiveness of the interventions based on periodic assessment of uniform outcome measures. Clinical and policy research about expanding internet-based mental health interventions should focus on confidentiality, efficacy, and cost-effectiveness.
  • ||||||||||  Journal:  Exploring the Interplay between Mitochondrial DNA and Lifestyle Factors in the Pathogenesis of Psychiatric Disorders. (Pubmed Central) -  Apr 14, 2025   
    In summary, the expression of mitochondrial genes could be modulated by lifestyle factors like smoking and drinking, potentially affecting psychiatric disorders. These habits might influence mitochondrial respiratory chain activity and the replication and transcriptional regulation of mitochondrial genes, culminating in changes in mitochondrial functionality and subsequently psychiatric disorders.
  • ||||||||||  Journal:  Shared and Unique Genetic Links between Neuroticism and Gastrointestinal Tract Diseases. (Pubmed Central) -  Apr 14, 2025   
    Our findings document the genetic links between neuroticism and six GIT diseases, highlighting the genetic overlaps and heterogeneity between neuroticism and psychiatric disorders in the context of gastrointestinal disorders. Both the shared and unique pleiotropic loci identified between neuroticism and different GIT diseases could facilitate mechanistic understandings and may stimulate further translational implications.
  • ||||||||||  Journal:  Social Dysfunction and Neural Processing of Emotional Valence Across Depressive and Anxiety Disorders. (Pubmed Central) -  Apr 14, 2025   
    Perceived loneliness scores did not correlate with brain activation to emotional faces. Taken together, perceived social disability across persons with and without depressive and/or anxiety disorders converges specifically on sad emotional processing of the left angular gyrus, suggesting a potential common neurobiological correlate for social dysfunction.
  • ||||||||||  Review, Journal:  The Pathologic Roles and Therapeutic Implications of Ghrelin/GHSR System in Mental Disorders. (Pubmed Central) -  Apr 14, 2025   
    Ghrelin binds to neurons in the ventral tegmental area (VTA), where it promotes the activity of dopamine neurons in the nucleus accumbens (NAcs) in a GHSR-dependent way, increasing dopamine levels and the reward system. This article summarized the recent research progress of ghrelin in depression, anxiety, schizophrenia, anorexia nervosa (AN), and bulimia nervosa (BN), and emphasized its potential application for psychiatric disorders treatment.
  • ||||||||||  Review, Journal:  Arx revisited: involved in the development of GABAergic interneurons. (Pubmed Central) -  Apr 14, 2025   
    These studies have identified Arx as a key transcriptional regulator involved in the generation, fate determination, and migration of cortical interneurons. This review focuses on the critical role of Arx in the development of progenitor cells and the migration of interneurons in the mouse OB and cerebral cortex, and discusses differences in Arx mutant-based abnormality between mouse mutants and human patients.
  • ||||||||||  Review, Journal:  Cell-type specific epigenetic and transcriptional mechanisms in substance use disorder. (Pubmed Central) -  Apr 14, 2025   
    We foresee the possibility of integrating multi-omics technologies to devise targeted and personalized therapeutic strategies aimed at both the prevention and treatment of SUD. By utilizing these advanced methodologies, we can gain a deeper understanding of the fundamental biology of SUD, paving the way for more effective interventions.
  • ||||||||||  Journal:  Genome Sequencing of Idiopathic Speech Delay. (Pubmed Central) -  Apr 14, 2025   
    In other probands in our speech delay cohort, likely pathogenic missense variants were identified affecting highly conserved amino acids in key functional domains of SPTBN1 and ARF3. Overall, this study expands the phenotype spectrum associated with pathogenic SETD1A variants, to also include idiopathic speech delay without CAS or intellectual disability, and suggests additional novel potential candidate genes that may harbour high-penetrance variants that can disrupt speech development.
  • ||||||||||  duloxetine / Generic mfg.
    P3 data, Review, Journal:  Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008-2024) and pipeline phase III medications. (Pubmed Central) -  Apr 14, 2025   
    Our review revealed that, in the past 16 years, the FDA approved only two medications for anxiety disorders (a delayed-release form of duloxetine for generalized anxiety disorder and an extended-release form of lorazepam) and none for PTSD or OCD...Our results showed a paucity of new medications for anxiety disorders and none for PTSD and OCD in the past 16 years. However, phase III psychiatric medications for anxiety disorders, PTSD and OCD seem to show several agents with novel mechanisms of action, various modes of administration, and improved side-effect profiles.
  • ||||||||||  Review, Journal:  Psychosocial stress and cardiovascular disease. (Pubmed Central) -  Apr 14, 2025   
    Besides the increase in incidence of traditional risk factors, such as smoking, hypertension, insulin resistance and obesity, several other pathophysiological mechanisms involving the neuro-endocrine, inflammatory and immune pathways may be responsible for the noted negative outcomes. In this manuscript we review some of the evidence linking social distress with adverse cardiovascular outcomes and the potential subtending mechanisms and therapeutic interventions.
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Journal:  Challenging the Safety Threshold: Neurotoxicity in Bipolar Disorder Treatment with Lithium at Therapeutic Serum Levels. (Pubmed Central) -  Apr 14, 2025   
    Lithium carbonate is widely used to prevent and treat the recurrence of bipolar disorder...This case reminds clinicians that even with normal serum lithium levels, toxic symptoms may occur, and close monitoring of the patient's clinical manifestations and serum lithium levels is essential. Additionally, poor diet and reduced sodium intake may increase the risk of lithium toxicity, so these factors should also be taken into consideration.
  • ||||||||||  Preclinical, Journal:  The Impact of Valproic Acid on Microbiota in a Mouse Model of Autism Spectrum Disorder. (Pubmed Central) -  Apr 14, 2025   
    These findings underscore the complex interplay between environmental factors, such as VPA, and the microbiota in the pathophysiology of ASD. The study lays the groundwork for future research aimed at developing targeted interventions to mitigate the symptoms of ASD and other neuropsychiatric disorders, potentially through modulating the microbiota-gut-brain axis.
  • ||||||||||  Review, Journal:  Prevalence of fragile X syndrome in South Asia, and importance of diagnosis. (Pubmed Central) -  Apr 14, 2025   
    Early diagnosis also facilitates genetic counselling and family planning, helping to reduce the risk of recurrence in families. Increased awareness and screening in South Asian communities are essential to address the diagnostic gap and ensure timely support for individuals with FXS or disorders associated with the premutation of FMR1.
  • ||||||||||  Review, Journal:  Incretin Mimetics (GLP-1 Agonists) as an Addition to the Psychopharmacology Armamentarium. (Pubmed Central) -  Apr 14, 2025   
    The exploration of GLP-1 receptor agonists as pleiotropic agents in the treatment of neuropsychiatric disorders and substance use disorders is a rapidly evolving field. While early studies have shown promising results, much of the research is still nascent, and larger clinical trials are definitely needed to confirm the safety and efficacy of these agents on real grounds.
  • ||||||||||  Journal:  Association of Human Endogenous Retrovirus HERV-K18 Variant with Bipolar Disorder Type I. (Pubmed Central) -  Apr 14, 2025   
    Moreover, the prevalence of the CC genotype in patients with hypomania (31.25%) was found to be higher than that observed in patients without hypomania (10.71%) (Fisher's exact test = 5.931, p = 0.036). This is the first study implying that HERV-K18 variations may be associated with the pathogenesis of BD-I.